zhulikou431December 25, 2018
Tag: Breast Cancer , treatments , conventional drugs
Treatments of breast cancer mainly include surgical treatment, chemotherapy, radioactive therapy, endocrine therapy, targeted therapy, TCM treatment, and immune preparation treatment, etc.
The conventional drugs include: common drugs such as Adriamycin, epirubicin, pirarubicin, and other anthracyclines; taxane chemotherapeutic drugs such as taxol and docetaxel; cyclophosphamide chemotherapeutic drugs; letrozole, anastrozole, docetaxel, capecitabine, gemcitabine, vinorelbine, cisplatin, and carboplatin, etc., all of which are important drugs in the breast cancer treatment area.
Targeted drugs and their classification:
Targeted therapies have merits such as strong specificity, significant efficacy, and small toxic and side effects. The main targets or pathways of the current targeted therapies for breast cancer include HER-2, VEGF, EGFR, PARP, PI3K/Akt/mTOR, and CDK4/6, etc.
Target/Pathway |
Classification |
Representative drug |
HER-2 (human epidermal growth factor receptor 2) |
Monoclonal antibody |
Trastuzumab, pertuzumab |
Small molecule tyrosine kinase inhibitor |
Lapatinib |
|
Monoclonal antibody combined with chemotherapeutic drug |
Trastuzumab-emtansine (TDM1) |
|
VEGF (vascular endothelial growth factor) |
Targeting VEGF |
Bevacizumab |
Targeting VEGFR2 |
Ramucirumab |
|
Multiple targets |
Sorafenib, sunitinib |
|
EGFR (epidermal growth factor receptor) |
Cetuximab, gefitinib, Tarceva (erlotinib) |
|
PI3K/Akt/mTOR (phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin) |
Temsirolimus, everolimus |
|
CDK4/6 (cyclin-dependent kinase 4 and 6) |
Palbociclib |
|
PARP inhibitor |
Olaparib |
|
Other new targeted drugs |
COX-2 (cyclooxygenase-2) |
|
HSP (heat shock protein) |
||
PD-1 and PD-L1 |
References:
1.Breast cancer clinical trials: top drugs under investigation
2. FDA website
Read more:
Breast cancer clinical trials: top drugs under investigation
Summary of main targeted drugs for breast cancer in the market
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: